Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to investigate expression and frequency of ABL point
mutations, a major cause of resistance in imatinib failed CML Asian patients and to find
causes of Asian-specific resistance to cancer-targeting therapies through a prospective
investigation of dynamics of point mutations and expression of new point mutations during
nilotinib treatment.